1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
The Institutional Development Awards (IDeA) program supports biomedical research capacity building in states that have historically received low levels of NIH funding. The Centers of Biomedical Research Excellence: Development Phase (COBRE-D) program supports institutions in IDeA states to increase their biomedical research capacity in a broad scientific area of strategic importance to them but for which they have limited existing infrastructure or expertise.COBRE-D supports a long-term institutional vision focused on the recruitment and mentoring of early-career investigators with supplemental start-up packages for new hires, the establishment of research facilities, and enhancement of research administration support services. This program serves as an on-ramp for less-resourced institutions to the Centers of Biomedical Research Excellence: Expansion/Sustainability Phases (COBRE-E/S) program. This is a Notice of Funding Opportunity (NOFO) for a Limited Competition that will invite application(s) from eligible organization(s) to apply. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered.
Funding Opportunity Number: PAR-27-054. Assistance Listing: 93.859. Funding Instrument: G. Category: HL.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Eligible applicants: Public and State controlled institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; Others (see text field entitled Additional Information on Eligibility for clarification). Eligibility is restricted to institutions that meet the following criteria:Are located in an IDeA-eligible state, commonwealth, or jurisdiction, which are Alaska, Arkansas, Delaware, Hawaii, Idaho, Kansas, Kentucky, Louisiana, Maine, Mississippi, Montana, Nebraska, Nevada, New Hampshire, New Mexico, North Dakota, Oklahoma, Puerto Rico, Rhode Island, South Carolina, South Dakota, Vermont, West Virginia, and Wyoming; andAward doctoral degrees in the health-related sciences or are independent biomedical research institutes/medical centers with ongoing biomedical research programs funded by the NIH or other federal agencies.Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. Note:Unfunded foreign components are allowed with prior approval.An unfunded foreign component would be a collaboration with investigators at a foreign site anticipated to result in co-authorship, when no IDeA funds are transferred via subcontract to an institution in a foreign country. Please also see NOT-OD-26-084.Foreign PIs or organizations may use center resources as a fee-for-service.In such cases, resulting publications cannot cite or acknowledge NIH grant support. Confirm the full requirements in the official notice before applying.
Applications for Limited Competition: Centers of Biomedical Research Excellence: Development Phase (COBRE-D) (P30 - Clinical Trial Not Allowed) are due May 26, 2029. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Yes — Limited Competition: Centers of Biomedical Research Excellence: Development Phase (COBRE-D) (P30 - Clinical Trial Not Allowed) is offered by National Institutes of Health and this listing comes from Grants.gov, an official U.S. federal source. Federal applications generally require registrations (for example SAM.gov or an agency submission portal), so allow extra lead time.
This opportunity targets applicants in 24 states, including Alaska, Arkansas, Delaware, Hawaii, and Idaho. Check the official notice for the full list.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Applications for a 3-year extension/renewal of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) clinical trial consortium are requested to fully meet the enrollment targets, complete participant follow-up, and finalize data analysis and dissemination of study findings. This Notice of Funding Opportunity (NOFO) invites a Single Source application for the eligible organization, the Scientific and Data Research Center (SDRC) already involved in the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Consortium. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered.There is currently no standard of care for patients after hospitalization with acute kidney injury (AKI). Successful completion of the COPE-AKI study will provide key insights that are expected to directly inform improved clinical management strategies and the development of standard of care for Stage 2 and 3 AKI survivors. Funding Opportunity Number: RFA-DK-27-139. Assistance Listing: 93.847. Funding Instrument: CA. Category: HL. Award Amount: $1.8M total program funding.
This is a Notice of Funding Opportunity (NOFO) for a Single Source that will invite an application from the eligible organization to apply. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, applications will be peer-reviewed, and only meritorious applications will be considered for funding. Through this NOFO, the National institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites an application to continue to follow the Epidemiology of Diabetes Interventions and Complications (EDIC) cohort through a collaborative cooperative agreement that addresses specific knowledge gaps in the development and progression of type 1 diabetes complications. Applications should include hypothesis-based research, support for cohort infrastructure and/or maintenance, continued follow-up, and supporting collaborative research to utilize the EDIC cohort as well as its data set and biologic/genetic samples. Funding Opportunity Number: RFA-DK-27-112. Assistance Listing: 93.847. Funding Instrument: CA. Category: HL. Award Amount: $6.3M total program funding.
NIH's RFI on administrative burden (NOT-OD-26-118) takes comments through December 8, 2026. It asks seven questions, lists eight reforms already made, and warns that responses may be posted unredacted. Here is what NIH is really asking for, what it can and cannot change alone, and how researchers and research offices should respond.
Read articleOn November 2, 2026, NIH released NOT-OD-27-006, a draft update to its Policy for Data and Safety Monitoring. As summarized by Harvard's research integrity office, the draft would extend risk-based monitoring from clinical trials to all NIH-supported clinical research, drop the blanket DSMB requirement for Phase 3 and multi-site trials, and require an NIH-approved monitoring plan scaled to risk, effective for applications six months after the final policy. Comments are due January 6, 2027. What it changes and how to respond.
Read articleR&D World's count of NIH RePORTER data shows 13,686 new awards in FY2026, up 21% from 11,272 in FY2025, while total extramural grants fell to about 56,600. New R01s hit 4,960. What the split means for FY2027 applicants.
Read article